Franklin Biotechnology Discv A(acc)SGD |
| Performance History | 31/03/2018 |
| Growth of 1,000 (ZAR) |
 | Fund | 48.9 | 40.5 | -27.3 | 5.7 | -4.5 |
| +/-Cat | 4.8 | -3.1 | 1.6 | -3.6 | -0.6 |
| +/-Idx | 4.4 | -3.7 | -4.9 | -1.3 | 2.5 |
| Category: Sector Equity Biotechnology | ||||||
| Category Benchmark: MSCI World/Biotechnology NR... | ||||||
| Key Stats | ||
| NAV 19/04/2018 | SGD 30.04 | |
| Day Change | -1.24% | |
| Morningstar Category™ | Sector Equity Biotechnology | |
| ISIN | LU0320765992 | |
| Fund Size (Mil) 31/03/2018 | USD 2175.16 | |
| Share Class Size (Mil) 31/03/2018 | SGD 26.89 | |
| Max Initial Charge | 5.75% | |
| Ongoing Charge 26/01/2018 | 1.81% | |
| Investment Objective: Franklin Biotechnology Discv A(acc)SGD |
| The Fund’s investment objective is capital appreciation. The Fund invests principally in equity securities of biotechnology companies and discovery research firms (including small to mid-sized companies) located in the US and other countries, and to a lesser extent in debt securities of any type of issuers worldwide. |
| Returns | |||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Steven Kornfeld 15/09/2015 | ||
Inception Date 25/10/2007 | ||
| Advertisement |
| Category Benchmark | |
| Fund Benchmark | Morningstar Benchmark |
| NASDAQ Biotechnology PR USD | MSCI World/Biotechnology NR USD |
| Target Market | ||||||||||||||||||||
| ||||||||||||||||||||
| Portfolio Profile for Franklin Biotechnology Discv A(acc)SGD | 31/03/2018 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Alexion Pharmaceuticals Inc |  Healthcare | 6.91 |
| Celgene Corp | Healthcare | 6.66 |
| Vertex Pharmaceuticals Inc | Healthcare | 4.86 |
| Biogen Inc | Healthcare | 4.62 |
| Illumina Inc | Healthcare | 3.79 |
 | ||
 Increase Decrease  New since last portfolio | ||
| Franklin Biotechnology Discv A(acc)SGD | ||
